Former AZ chief David Brennan expected to take over as chairman in May.
MPs to discuss controversial plan in special debate.
Technical officer hinted that the firm has hit obstacles to its ambitious projects.
New cost-capping and delaying measures will further restrict access to new medicines say pharma and patient groups.
Pharma needs a full picture of insights from all stakeholders, including patients, from the earliest stages of the product lifecycle.
02/11/2016November 1, 2016
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.